Source:http://linkedlifedata.com/resource/pubmed/id/18068095
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2007-12-10
|
pubmed:abstractText |
OK-432 (Picibanil), a Streptococcal immunotherapeutic agent, has been used for immunotherapy of various cancers as a biological response modifier (BRM). However, OK-432 contains multiple components consisting of immunotherapeutic ones and contaminants which may weaken the effects or exert side-effects. In this study, we investigated extraction of contaminants from OK-432 using Triton X-114 (TX-114)-water phase partitioning and examined an antitumor effect of the resulting preparation. OK-432 was subjected to TX-114 partitioning to give residual precipitate designated as OK-TX-ppt. OK-TX-ppt exerted no TLR2-mediated activity, but induced interleukin (IL)-6 in human PBMC. OK-TX-ppt also induced tumor necrosis factor (TNF)-alpha, IL-10, IL-12, and interferon (IFN)-gamma in PBMC. Moreover, IFN-gamma-inducing activity of OK-TX-ppt was significantly higher and IL-10 production was lower than that of OK-432. In tumor-bearing mice model, administration of OK-TX-ppt i.p. extended the survival time of Meth-A-bearing mice compared to OK-432. OK-TX-ppt also increased the levels of IL-12 and IFN-gamma in mouse spleen cells in vitro. These results indicated that TX-114 partitioning removed some contaminants, which attenuates the antitumor effect, from OK-432 and increase the immunotherapeutic effects of OK-432.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Pharmaceutic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Nonidet P-40,
http://linkedlifedata.com/resource/pubmed/chemical/Picibanil,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1567-5769
|
pubmed:author |
pubmed-author:FuruyashikiMaikoM,
pubmed-author:HashimotoMasahitoM,
pubmed-author:IjichiShinjiS,
pubmed-author:KawamuraYutakaY,
pubmed-author:KoideHiroyukiH,
pubmed-author:KusumotoShoichS,
pubmed-author:MoriokaHirofumiH,
pubmed-author:MoriyaYoichiroY,
pubmed-author:OkuNaotoN,
pubmed-author:SanoRyokoR,
pubmed-author:SudaYasuoY,
pubmed-author:TakashigeKatsuhiroK,
pubmed-author:YoshidomeKeitaroK
|
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
12-9
|
pubmed:meshHeading |
pubmed-meshheading:18068095-Adjuvants, Pharmaceutic,
pubmed-meshheading:18068095-Animals,
pubmed-meshheading:18068095-Antineoplastic Agents,
pubmed-meshheading:18068095-Cell Line, Tumor,
pubmed-meshheading:18068095-Cells, Cultured,
pubmed-meshheading:18068095-Humans,
pubmed-meshheading:18068095-Male,
pubmed-meshheading:18068095-Mice,
pubmed-meshheading:18068095-Mice, Inbred BALB C,
pubmed-meshheading:18068095-Neoplasms, Experimental,
pubmed-meshheading:18068095-Picibanil,
pubmed-meshheading:18068095-Polyethylene Glycols
|
pubmed:year |
2008
|
pubmed:articleTitle |
Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
|
pubmed:affiliation |
Department of Nanostructure and Advanced Materials, Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Korimoto, Kagoshima 890-0065, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|